Cingulate Inc. shares surged 30.7% amid strong investor interest in its ADHD treatment technology. Trading volume was high, with 3.297 million shares traded, reflecting growing market attention. Don’t ...

Cingulate, Inc. (NASDAQ:CING) reported third quarter 2025 results on November 13 th, 2025. No revenues were recorded and operating expense totaled $6.0 million. The new drug application (NDA) to the ...

Cingulate Inc. CING shares were down during Friday’s premarket session but recovered later. The company’s recent financial report highlighted both operational advancements and ongoing challenges. The ...

Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...

Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING).

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...